CASIA OpenIR

Browse/Search Results:  1-2 of 2 Help

Selected(0)Clear Items/Page:    Sort:
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors 期刊论文
BMC Medicine, 2022, 卷号: 20, 期号: 1
Authors:  Zhang,Pei;  Du,Yang;  Bai,Hua;  Wang,Zhijie;  Duan,Jianchun;  Wang,Xin;  Zhong,Jia;  Wan,Rui;  Xu,Jiachen;  He,Xiran;  Wang,Di;  Fei,Kailun;  Yu,Ruofei;  Tian,Jie;  Wang,Jie
Favorite  |  View/Download:25/0  |  Submit date:2022/11/21
Tucidinostat  Tumor microenvironment  PD-L1  CCL5  Solid tumor  
Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma 期刊论文
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 卷号: 8, 期号: 2, 页码: 15
Authors:  He, Xiran;  Du, Yang;  Wang, Zhijie;  Wang, Xin;  Duan, Jianchun;  Wan, Rui;  Xu, Jiachen;  Zhang, Pei;  Wang, Di;  Tian, Yanhua;  Han, Jiefei;  Fei, Kailun;  Bai, Hua;  Tian, Jie;  Wang, Jie
Favorite  |  View/Download:62/0  |  Submit date:2021/01/06
drug therapy  combination  immunotherapy  lung neoplasms  lymphocytes  tumor-infiltrating  translational medical research